Sign Out
There are no data from the use of Rasagiline in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo-fetal development, delivery and postnatal development. Rasagiline Tablets should be used only if the potential benefit justifies the potential risk to the fetus.
Non-clinical data indicate that rasagiline inhibits prolactin secretion and thus, may inhibit lactation. It is not known whether rasagiline is excreted in human milk. Caution should be exercised when rasagiline is administered to a breast-feeding mother.
Continue with Google